Cytokinetics | CYTK - Assets


Cytokinetics reported $1.27B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Arca Biopharma USD 504.48M 15.86M Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
Brainstorm Cell Therapeutics USD 755K 267K Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Capricor Therapeutics USD 326.28M 29.66M Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Eisai JPY 1.45T 37.11B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Exelixis USD 2.59B 250.83M Mar/2026
Geron USD 534.12M 36.42M Mar/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Ligand Pharmaceuticals USD 1.53B 28.53M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 128.02B 1.22B Mar/2026